Glycotest Licenses IP from S. Carolina university
For announcement on Reach: 07.00 a.m., 13 October 2026
EMV Capital plc
(EMVC or the Company)
Glycotest Licenses Novel Biomarker Intellectual Property from the Medical University of South Carolina
To Advance Next-Generation Liver Fibrosis Staging Test
EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, announces that its portfolio company Glycotest has executed a licence agreement with the Zucker Institute for Innovation Commercialization (ZI), the commercialisation entity advancing technologies originated from the Medical University of South Carolina (MUSC), for intellectual property relating to Glycotest’s blood test for staging liver fibrosis.
The licensed IP supports the expansion of Glycotest’s proprietary LRAGG biomarker into multi-biomarker panels with the potential for greater clinical performance and extended patent protection.
Under the terms of the agreement, Glycotest receives exclusive worldwide rights to the licensed intellectual property, and ZI will receive a royalty on future product sales, along with other financial consideration.
Accurate staging of liver fibrosis is essential to managing patients with chronic liver disease, helping guide treatment decisions and monitor disease progression. The need for accessible, effective fibrosis assessment is particularly acute in the rapidly growing population with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), where identifying clinically meaningful fibrosis before progression to advanced disease can inform patient management.
MASLD affects an estimated 100 million US adults and more than 1 billion people worldwide, creating a substantial and growing need for non-invasive fibrosis assessment. Clinical guidelines recommend periodic fibrosis assessment for at-risk patients, representing a global market opportunity projected* to reach as high as $3 billion by 2033.
Through its clinical laboratory services business model, Glycotest is committed to providing physicians and patients with convenient, objective, blood-based tools for liver fibrosis staging.
The newly licensed intellectual property was developed by Professor Anand Mehta, DPhil, who holds the SmartState Chair in Proteomic Biomarkers at MUSC and is a recognised leader in the discovery and validation of glycoprotein and proteomic biomarkers for liver disease.
Liver fibrosis affects millions of patients worldwide, with rising prevalence driven in large part by the growing burden of MASH. Non-invasive, blood-based staging tools are increasingly viewed as essential to identifying patients who require closer monitoring or intervention before disease progresses to cirrhosis, the point at which treatment options narrow considerably.
Charles Swindell, PhD, CEO, Glycotest, commented:
“This license agreement with the Zucker Institute is an important step in strengthening our liver fibrosis staging pipeline. By expanding our proprietary LRAGG biomarker into a multi-biomarker panel, we believe we can deliver even greater clinical performance while extending the intellectual property protection around our technology. We are excited to work with Professor Mehta and his team, whose deep expertise in glycoproteomic biomarker discovery is highly complementary to our mission of bringing novel non-invasive tests to patients with liver disease.”
Anand Mehta, DPhil, SmartState Chair in Proteomic Biomarkers, MUSC, said:
“Our research has focused on identifying biomarkers that can meaningfully improve the accuracy of non-invasive liver fibrosis staging, particularly for patients in the intermediate stages of disease who stand to benefit most from early intervention. Licensing this intellectual property to Glycotest gives it a clear path toward the clinic, and I look forward to collaborating with their team to advance a next-generation, multi-biomarker panel that builds on the LRAGG platform.”
Dr Ilian Iliev, CEO of EMV Capital, said:
“This agreement is a good example of the Glycotest team methodically building value. By adding to its fibrosis programme and IP protection, the company is extending a diagnostics platform through IP-led, capital-efficient growth, which is central to EMV Capital’s investment thesis. We look forward to supporting the team as they work towards becoming a standard in liver diagnostics.”
*Grand View Research, Hepatic Fibrosis Biomarkers Market Analysis Report (2025–2033); Coherent Market Insights, Transient Elastography Devices Market Forecast
-Ends-
For more information, please contact:
|
|
|
|
EMV Capital plc |
via Rosewood |
|
Ilian Iliev, CEO |
|
|
|
|
|
Panmure Liberum Limited (NOMAD and Broker) |
+44 (0)20 7886 2500 |
|
Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance) |
|
|
Rupert Dearden (Corporate Broking) |
|
|
|
|
|
Rosewood (Financial PR) |
+44 (0)20 7653 8702 |
|
John West / Llew Angus |
|
About EMV Capital plc (EMVC)
EMV Capital plc is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies. With a focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future, EMV Capital invests in, manages and strengthens early-stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
capital-efficient investments through Group balance sheet;
fund management of the Evergreen EIS and Martlet Capital Funds;
syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company with a pipeline of clinical-stage blood tests for hepatocellular carcinoma, cholangiocarcinoma and fibrosis. The Company is focused on the estimated $4 billion global liver cancer surveillance and fibrosis staging market. Glycotest was spun out of the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine and is backed by the London-based VC investor EMV Capital and other private investors.
Learn more at https://www.glycotest.com
About the Medical University of South Carolina
The Zucker Institute for Innovation Commercialization is the commercialisation organisation for the Medical University of South Carolina (MUSC), working to translate MUSC discoveries into products, services and companies that improve health and generate economic impact. The Zucker Institute manages MUSC intellectual property and works with faculty, entrepreneurs, investors and industry partners to advance promising innovations toward the marketplace.
Learn more at https://www.zuckerinnovation.org/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE